Publications

Find at Harvard

02 Mar 2007
What Do You Think?

What Is the Government’s Role in US Health Care?

Newman), the high cost of new technology, artificial restrictions on the supply of drugs (Sergey Mirkiin) and healthcare providers (David Stahl and Michael Robbins), the size and complexity of the problem... View Details

Keywords: by Jim Heskett; Health

January 2021
Case

Value-Based Insurance Design at Onex

By: Joshua Schwartzstein, Amitabh Chandra and Amram Migdal

The operating executives of Health and Benefits for Onex Partners, Megan Jackson Frye and Sam Camens, faced a challenge: Healthcare costs for employees of Onex’s portfolio companies were continuing to rise above the consumer price index, reflecting broader trends... View Details

24 Sep 2007
Research & Ideas

The FDA: What Will the Next 100 Years Bring?

The U.S. Food and Drug Administration, which was created by the passage of the 1906 Federal Food and Drugs Act, regulates companies and industries accounting for one-quarter of all consumer spending, roughly... View Details

Keywords: by Sean Silverthorne; Biotechnology; Consumer Products; Food & Beverage; Health

07 Dec 2010
First Look

First Look: Dec. 7

to value the expected costs of issuing a loan guarantee. Purchase this case:http://cb.hbsp.harvard.edu/cb/product/211032-PDF-ENG Chances Are? Hanna W. Halaburda and Aldo Sesia Jr.Harvard Business School Case 711-417 The case describes two... View Details

Keywords: Sean Silverthorne

June 2024
Article

Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices

By: Jason Shafrin, Jaehong Kim, Joshua T. Cohen, Louis P. Garrison, Dana A. Goldman, Jalpa A. Doshi, Joshua Krieger, Darius N. Lakdawalla, Peter J. Neumann, Charles E. Phelps, Melanie D. Whittington and Richard Willke

This study argues that value assessment conducted from a societal perspective should rely on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein. Recently developed value assessment inventories—such as the Second Panel on Cost-Effectiveness’s... View Details

Keywords: Health Care and Treatment; Valuation; Cost vs Benefits; Society

Read Now

October 2024
Case

Parexel: Scaling Up and Industry Dynamics

By: Regina E. Herzlinger and Ben Creo

Through the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small, secondary cluster of firms into a major player with... View Details

Keywords: Research; Innovation and Invention; Business Model; Transformation; Globalization; Information Technology; Competitive Advantage; Pharmaceutical Industry

April 2009 (Revised May 2010)
Case

Partners In Health: HIV Care in Rwanda

By: Michael E. Porter, Scott S. Lee, Joseph Rhatigan and Jim Yong Kim

In 2005, Partners in Health (PIH) was invited by the Rwandan Ministry of Health to assume responsibility for the management of public health care in two rural districts in Eastern Rwanda and create an HIV treatment program at these sites. PIH successfully implemented a... View Details

Keywords: Developing Countries and Economies; Health Care and Treatment; Health Testing and Trials; Medical Specialties; Service Delivery; Nonprofit Organizations; Expansion; Health Industry; Rwanda

29 Oct 2013
First Look

First Look: October 29

scheme, more extensive than any previously revealed in professional sports history." Until that moment with Oprah, Armstrong had consistently and strenuously denied using performance enhancing drugs (PEDs), blood transfusions, or... View Details

Keywords: Sean Silverthorne

16 Jul 2008
Op-Ed

What Should Employers Do about Health Care?

frequently in search of a better deal, which has meant that their employees needed to switch as well. They have tried to pare back covered services, thrown up barriers to expensive drugs and treatments, and recently, begun to pass more... View Details

Keywords: by Michael E. Porter, Elizabeth O. Teisberg & Scott Wallace; Health

February 2003 (Revised April 2004)
Case

Pharmaceutical Industry, The: Challenges in the New Century

By: Stephen P. Bradley and James Weber

Provides a broad overview of the numerous internal and external forces that were driving change in the global pharmaceutical industry in 2003. These forces--including downward price pressures, political and social pressures, increased development costs, new... View Details

Keywords: Business Model; Change; Cost; Price; Globalization; Government and Politics; Brands and Branding; Industry Growth; Society; Competition; Consolidation; Technology; Pharmaceutical Industry

15 Jan 2019
First Look

New Research and Ideas, January 15, 2019

December 19, 2018 NEJM Catalyst It's Time to Reform the Orphan Drug Act By: Bagley, Nicholas, Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern Abstract—No abstract available. Publisher's link:... View Details

Keywords: Dina Gerdeman

15 Dec 2014
Research & Ideas

Deconstructing the Price Tag

expenses incurred. For example, R&D expenditures in the pharmaceutical industry involve more than just the cost of producing one particular drug. Many drugs may have to fail before one succeeds, and that... View Details

Keywords: by Dina Gerdeman; Retail

14 Jul 2006
Op-Ed

The Case for Consumer-Driven Medicaid

for the private sector's consumer-driven experiences with lower-income populations, the experience of Whole Foods, a supermarket chain, is instructive. As of 2004, its employees, primarily blue collar, have saved $14 million in health savings accounts, while View Details

Keywords: by Regina E. Herzlinger

10 Nov 2020
Sharpening Your Skills

Research News and Tips: Innovating Across Time Zones

minimize temporal distance—that is, largely on a North-South axis,” the paper says. Read the paper: The Effects of Temporal Distance on Intra-Firm Communication: Evidence from Daylight Savings Time. Jasmina Chauvin, Prithwiraj Choudhury, and Tommy Fan Pang. Immigrant... View Details

Keywords: by Sean Silverthorne

January–February 2023
Article

Data-Driven COVID-19 Vaccine Development for Janssen

By: Dimitris Bertsimas, Michael Lingzhi Li, Xinggang Liu, Jennings Xu and Najat Khan

The COVID-19 pandemic has spurred extensive vaccine research worldwide. One crucial part of vaccine development is the phase III clinical trial that assesses the vaccine for safety and efficacy in the prevention of COVID-19. In this work, we enumerate the first... View Details

Keywords: COVID-19; Health Testing and Trials; Forecasting and Prediction; AI and Machine Learning; Research; Pharmaceutical Industry

Find at Harvard

December 2012
Article

On the Efficiency-Fairness Trade-Off

By: Dimitris Bertsimas, Vivek F. Farias and Nikolaos Trichakis

This paper deals with a basic issue: How does one approach the problem of designing the "right" objective for a given resource allocation problem? The notion of what is right can be fairly nebulous; we consider two issues that we see as key: efficiency and fairness. We... View Details

Keywords: Decision Support; Cost vs Benefits; Fairness; Resource Allocation; Performance Efficiency; Air Transportation Industry